Format

Send to

Choose Destination
Turk Kardiyol Dern Ars. 2015 Jan;43(1):78-81. doi: 10.5543/tkda.2015.41763.

Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.

Author information

1
Department of Cardiology, Gazi University Faculty of Medicine, Ankara, Turkey. gtacoy@yahoo.com.
2
Department of Cardiology, Gazi University Faculty of Medicine, Ankara, Turkey.
3
Department of Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.

Abstract

Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary arterial pressure ≥25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is characterized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment.

PMID:
25655855
DOI:
10.5543/tkda.2015.41763
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Kare Publishing
Loading ...
Support Center